The Five-Year Option PTC Is Selling to Delay Its Bill

PTC Therapeutics announced a $500 million convertible notes offering maturing in 2031 and said it would use the proceeds to retire maturing 2026 convertible debt and buy back roughly $50 million of its own shares. The refinancing part makes sense. The buyback part makes it interesting.